Skip to main content

Table 1 Baseline demographics and clinical characteristics (randomized set, observed cases)

From: Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis

  All randomized patients (n = 409)
Demographic characteristics
  Age (years) 47.6 ± 11.4
  Sex (% female) 55.3
  Race (% white) 97.8
  Weight (kg) 84.4 ± 18.8
  Body mass index (kg/m2) 29.8 ± 6.5
Arthritis characteristics
  Time from psoriatic arthritis diagnosisa (years) 8.6 ± 8.2
  C-reactive proteinb (mg/l) 8.0 (0.1 to 238.0)
  Mean tender joint count (0 to 68 joints) 20.3 ± 14.9
  Mean swollen joint count (0 to 66 joints) 10.7 ± 8.0
  Physician’s Assessment of Disease Activity, by VAS (mm) 57.9 ± 18.6
  Patient’s Assessment of Disease Activity 59.1 ± 20.7
  Patient’s Assessment of Arthritis Pain, by VAS (mm) 60.3 ± 20.4
  DAS28 (CRP) 5.0 ± 1.0
  Mean HAQ-DI (range 0 to 3) 1.31 ± 0.64
Psoriasis characteristics
  Psoriasis BSA ≥3% (%) 61.6
  PASIc 11.7 ± 11.9
  Prior use of synthetic DMARDs (%) 50.6
  1 47.2
  ≥2  
  Prior TNF inhibitor exposure (%) 19.6
Health-related quality of life
  Mean SF-36 MCS 41.7 ± 12.1
  Mean SF-36 PCS 33.4 ± 7.7
  Mean PsAQoL 11.1 ± 5.6
  Mean DLQI 8.5 ± 7.2
  Mean EQ-5D VAS 49.9 ± 20.4
  1. Data presented as mean ± SD, percentage or median (minimum to maximum). BSA, body surface area; DAS28(CRP), Disease Activity Score – 28-joint count based on C-reactive protein; DLQI, Dermatology Life Quality Index; DMARD, disease-modifying antirheumatic drug; EQ-5D, EuroQoL-5 dimensions; HAQ-DI, Health Assessment Questionnaire – Disability Index; MCS, mental component summary; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, Psoriatic Arthritis Quality of Life; SF-36, Short Form-36 items; TNF, tumor necrosis factor; VAS, visual analogue scale. aFrom the start date of the primary disease. bNormal range < 8.0 mg/l. cPASI scores are presented for patients with psoriasis body surface area ≥ 3% at baseline.